The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man.
1. The single (250 and 500 mg) and multiple dose (250 and 500 mg twice daily for 15 days) pharmacokinetics of diflunisal were compared in young volunteers. 2. The plasma clearance of diflunisal was lowered significantly after multiple dose administration (5.2 +/- 1.2 and 4.2 +/- 0.7 ml min-1 for the 250 and 500 mg twice daily regimens, respectively) as compared with single dose administration 11.4 +/- 3.1 and 9.9 +/- 2.0 ml min-1 for the 250 and 500 mg single doses, respectively). 3. The partial metabolic clearances of diflunisal by acyl and phenolic glucuronide formation were lowered significantly (greater than 50%) after multiple dose administration. 4. The urinary recovery of diflunisal sulphate increased as a function of dose: 6.1 +/- 2.8 and 9.1 +/- 3.5% following the 250 and 500 mg single dose, respectively, and 10.9 +/- 3.1 and 15.9 +/- 3.6% following the 250 and 500 mg twice daily regimens. The partial metabolic clearance of diflunisal by sulphate conjugation was unchanged following multiple dose administration. 5. The plasma protein binding of diflunisal was concentration-dependent. Analysis of unbound plasma clearances of diflunisal showed that its total plasma clearance following 500 mg twice daily was affected by both saturable glucuronidation and concentration-dependent plasma binding.
Verbeeck
R K
RK
College of Pharmacy, University of Saskatchewan, Saskatoon, Canada.
Loewen
G R
GR
MacDonald
J I
JI
Herman
R J
RJ
D000293:Adolescent; D000328:Adult; D001798:Blood Proteins / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D004061:Diflunisal / Q000378:metabolism* / Q000493:pharmacokinetics; D005965:Glucuronates / Q000378:metabolism; D006801:Humans; D008297:Male; D011485:Protein Binding
D001798:Blood Proteins; D005965:Glucuronates; D004061:Diflunisal